摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-2-methylsulfanyl-4-oxo-1,4-dihydroquinoline-3-carboxylate | 922492-57-7

中文名称
——
中文别名
——
英文名称
ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-2-methylsulfanyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
英文别名
Ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-2-(methylthio)-4-oxo-1,4-dihydroquinoline-3-carboxylate;ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-2-methylsulfanyl-4-oxoquinoline-3-carboxylate
ethyl 1-cyclopropyl-6,7-difluoro-8-methoxy-2-methylsulfanyl-4-oxo-1,4-dihydroquinoline-3-carboxylate化学式
CAS
922492-57-7
化学式
C17H17F2NO4S
mdl
——
分子量
369.389
InChiKey
KLHXTXHRUNCQAL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    81.1
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES
    申请人:Bradbury James Barton
    公开号:US20080071086A1
    公开(公告)日:2008-03-20
    The present invention provides process for synthesis of 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones of the Formula A. The substituents R, R 5 , R 6 , R 7 , R 8 and R 9 are defined herein. The invention also provides novel synthetic intermediates useful in the synthesis of 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones.
    本发明提供了一种合成式A中的8-甲氧基-9H-异噻唑并[5,4-b]喹啉-3,4-二酮和8A,9-二氢-4aH-异噻唑并[5,4-b]喹啉-3,4-二酮的过程。其中,取代基R、R5、R6、R7、R8和R9在此定义。本发明还提供了一种新的合成中间体,用于合成8-甲氧基-9H-异噻唑并[5,4-b]喹啉-3,4-二酮和8A,9-二氢-4aH-异噻唑并[5,4-b]喹啉-3,4-二酮。
  • 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
    申请人:Bradbury James Barton
    公开号:US20070049586A1
    公开(公告)日:2007-03-01
    The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.
    本发明提供了公式I和II的化合物和盐,其中包括公式A和公式B的化合物:这些化合物具有有用的抗微生物活性。公式A和B中显示的变量R2、R3、R5、R6、R7和R9在此定义。本文所披露的公式I和公式II的某些化合物是强效和/或选择性的细菌DNA合成和细菌复制抑制剂。本发明还提供了抗微生物组合物,包括含有公式I或公式II中一个或多个化合物和一个或多个载体、赋形剂或稀释剂的制药组合物。这些组合物可以仅包含公式I或公式II中的一个化合物作为唯一活性剂,也可以包含公式I或公式II中的一个化合物和一个或多个其他活性剂的组合物。本发明还提供了治疗动物微生物感染的方法。
  • 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS
    申请人:Bradbury Barton James
    公开号:US20120040959A1
    公开(公告)日:2012-02-16
    The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.
    本发明提供了公式I和II的化合物和盐,其中包括公式A和公式B的化合物:这些化合物具有有用的抗微生物活性。 公式A和B中显示的变量R2、R3、R5、R6、R7和R9在此定义。 本文所披露的某些公式I和公式II的化合物是细菌DNA合成和细菌复制的有效和/或选择性抑制剂。 本发明还提供了抗微生物组合物,包括含有一个或多个公式I或公式II化合物的制药组合物和一个或多个载体、赋形剂或稀释剂。 这样的组合物可以仅包含公式I或公式II的化合物作为唯一活性剂,也可以包含公式I或公式II的化合物和一个或多个其他活性剂的组合物。 本发明还提供了治疗动物微生物感染的方法。
  • Isothiazoloquinolones with Enhanced Antistaphylococcal Activities against Multidrug-Resistant Strains:  Effects of Structural Modifications at the 6-, 7-, and 8-Positions
    作者:Qiuping Wang、Edlaine Lucien、Akihiro Hashimoto、Godwin C. G. Pais、David M. Nelson、Yongsheng Song、Jane A. Thanassi、Christopher W. Marlor、Christy L. Thoma、Jijun Cheng、Steven D. Podos、Yangsi Ou、Milind Deshpande、Michael J. Pucci、Douglas D. Buechter、Barton J. Bradbury、Jason A. Wiles
    DOI:10.1021/jm060844e
    日期:2007.1.1
    We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl)-9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 mu g/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.
  • WO2007/14308
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多